Prime Medicine (PRME) Return on Capital Employed (2022 - 2026)

Prime Medicine's Return on Capital Employed history runs 5 years deep, the most recent figure standing at 73.15% for Q1 2026.

• Quarterly Return on Capital Employed rose 99.0% year-over-year to 73.15% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 73.15% (up 99.0% YoY) and the FY2025 annual result came in at 73.71%, up 2376.0% from the prior year.
• Return on Capital Employed was 73.15% for Q1 2026 at Prime Medicine, down from 63.83% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 43.42% in Q1 2023 and bottomed at 127.94% in Q4 2023.
• A 5-year average of 74.79% and a median of 73.65% in 2025 frame the typical range for Return on Capital Employed.
• Annual changes were most pronounced in 2023 — Return on Capital Employed tumbled 8330 bps — and 2024, when it jumped 5489 bps.
• Prime Medicine's Return on Capital Employed stood at 44.64% in 2022, then sank by 187 bps to 127.94% in 2023, then soared by 43 bps to 73.04% in 2024, then advanced by 13 bps to 63.83% in 2025, then fell by 15 bps to 73.15% in 2026.
• Business Quant data shows PRME's Return on Capital Employed at 73.15% in Q1 2026, 63.83% in Q4 2025, and 68.68% in Q3 2025.